Devalingam Mahalingam
Northwestern University · The University of Texas Health Science Center at San Antonio · University of Texas, Health Science Center, Cancer Therapy and Research Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Devalingam Mahalingam as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:15 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07594626 · BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP DeletionNorthwestern University · recruiting · Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma · principal investigator
- Ph1/Ph2NCT07042919 · Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver CancerDevalingam Mahalingam · recruiting · Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8 · principal investigator
- Ph2NCT06630416 · Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid TumorsNorthwestern University · recruiting · Metastatic Bladder Urothelial Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Bladder Cancer AJCC v8 · principal investigator
- Ph2NCT05733000 · CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsNorthwestern University · recruiting · Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph2NCT05576896 · Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer RefractoryNorthwestern University · terminated · Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV · principal investigator
- Ph1/Ph2NCT05251038 · Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas CancerDevalingam Mahalingam · withdrawn · Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer · principal investigator
- Ph2NCT03723915 · Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic CancerNorthwestern University · terminated · Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 · principal investigator
- N/ANCT02082691 · Continued Administration of G-202 for One Patient With Advanced Hepatocellular CarcinomaDevalingam Mahalingam · no longer available · Hepatocellular Carcinoma · principal investigator
- Ph2NCT01777594 · Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular CarcinomaGenSpera, Inc. · completed · Advanced Adult Hepatocellular Carcinoma · study chair
- Ph2NCT01620593 · Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate CancerThe University of Texas Health Science Center at San Antonio · completed · Prostate Cancer · principal investigator
- Ph1NCT01056029 · Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid TumorsGenSpera, Inc. · completed · Advanced Solid Tumors · principal investigator
- Ph2NCT00984464 · Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaOncolytics Biotech · completed · Metastatic Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data ManagementP30CA060553 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2022 to 2026 · $889,375 awarded in 2026Grant number is on one of their registry trials
- Inhibition of Autophagy: A Novel Therapeutic Strategy for Advanced Solid TumorsR21CA139476 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2010 · $321,474 awarded in 2010Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:15 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- 254 citationsRCR 7.2
- 70 citationsRCR 3.5
- Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).Br J Cancer · 202239 citationsRCR 2.8
- Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?J Gastrointest Cancer · 20182 citationsRCR 0.1